Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up

Radka Saldova, Vilde D. Haakensen, Einar Rødland, Ian Walsh, Henning Stöckmann, Olav Engebraaten, Anne Lise Børresen-Dale, Pauline M. Rudd

    Research output: Contribution to journalArticle

    5 Scopus citations


    Using our recently developed high-throughput automated platform, N-glycans from all serum glycoproteins from patients with breast cancer were analysed at diagnosis, after neoadjuvant chemotherapy, surgery, radiotherapy and up to 3 years after surgery. Surprisingly, alterations in the serum N-glycome after chemotherapy were pro-inflammatory with an increase in glycan structures associated with cancer. Surgery, on the other hand, induced anti-inflammatory changes in the serum N-glycome, towards a noncancerous phenotype. At the time of first follow-up, glycosylation in patients with affected lymph nodes changed towards a malignant phenotype. C-reactive protein showed a different pattern, increasing after first line of neoadjuvant chemotherapy, then decreasing throughout treatment until 1 year after surgery. This may reflect a switch from acute to chronic inflammation, where chronic inflammation is reflected in the serum after the acute phase response subsides. In conclusion, we here present the first time-course serum N-glycome profiling of patients with breast cancer during and after treatment. We identify significant glycosylation changes with chemotherapy, surgery and follow-up, reflecting the host response to therapy and tumour removal.

    Original languageEnglish (US)
    Pages (from-to)1361-1379
    Number of pages19
    JournalMolecular oncology
    Issue number10
    StatePublished - Oct 2017


    • CRP
    • breast cancer
    • follow-up
    • inflammation
    • serum N-glycans
    • treatment

    ASJC Scopus subject areas

    • Molecular Medicine
    • Genetics
    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up'. Together they form a unique fingerprint.

  • Cite this

    Saldova, R., Haakensen, V. D., Rødland, E., Walsh, I., Stöckmann, H., Engebraaten, O., Børresen-Dale, A. L., & Rudd, P. M. (2017). Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up. Molecular oncology, 11(10), 1361-1379.